The SPAARK trial has now received OCTRU Green Light approval and can begin recruitment! This is a phase III, multi-centre, patient blinded, randomised controlled trial to evaluate the effectiveness of liposomal bupivacaine with bupivacaine hydrochloride compared to bupivacaine hydrochloride alone on post-operative recovery after knee replacement surgery.
SPAARK trial opens to recruitment
OCTRU
23 January 2018